OKYO Pharma Achieves 90% Enrollment In 240-Patient Phase 2 Clinical Trial Of OK-101 To Treat Dry Eye Disease
Portfolio Pulse from Benzinga Newsdesk
OKYO Pharma Limited (NASDAQ:OKYO) has achieved 90% enrollment in its 240-patient Phase 2 clinical trial of OK-101 to treat Dry Eye Disease (DED). The company is developing OK-101 to address the significant unmet need in the multi-billion-dollar DED market.

August 30, 2023 | 11:04 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
OKYO Pharma's progress in the Phase 2 clinical trial of OK-101 could potentially boost its stock as it signifies progress in addressing a significant unmet need in the DED market.
The progress in the Phase 2 clinical trial signifies that OKYO Pharma is on track with its development of OK-101. This could potentially attract investors who are interested in the DED market, thereby boosting the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100